KALA Bio completes enrollment in CHASE trial, advancing KPI-012 for treating persistent corneal epithelial defects. Topline ...

Krystal Biotech climbs after dosing begins in a phase I/II trial for KB801, a gene therapy eye drop targeting neurotrophic keratitis.

Topline results from the CHASE trial expected by end of Q3 2025 -- -- Potential for CHASE to serve as a pivotal trial in support of a Biologics License Application (BLA) submission, contingent on ...

Eye drop administration of KB801 designed to enable sustained expression of NGF in the front of the eye Investor call and webcast to be held July 9 at 8:30 am ET to discuss program and trial design PI ...

PITTSBURGH, July 09, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that the first patient has been dosed in its Phase 1/2 clinical trial (“EMERALD-1”), ...

Amgen's Phase 3 trial of bemarituzumab plus chemo met its survival goal in FGFR2b+ gastric cancer, with full data expected ...

Amgen (AMGN) announced on Monday that a late-stage study evaluating its Bemarituzumab in combination with chemotherapy met ...

This study investigates the impact of interface defects on the electrical performance of epoxy-impregnated aramid papers (EAPs). Various composites with different degrees of defects were prepared and ...

Managing Upper and Lower Airway Diseases: The Role of Epithelial-Driven Inflammation This activity is supported by an independent educational grant from AstraZeneca Pharmaceuticals.

“The Defects” writer Ahn So Jung has shared behind-the-scenes stories about the upcoming series! Based on a popular webtoon, “The Defects” is an action ...

By remodeling the epithelial barrier, this bioadhesive hydrogel provides a promising strategy for corneal homeostasis preservation and ocular disorder prevention.

Corneal ulcer occurs in 10% of the population of VKC patients. If left untreated, a plaque containing fibrin and mucus is deposited over the epithelial defect.